[go: up one dir, main page]

CO6190618A2 - Compuestos de piridina y su uso como antagonistas de p2 y12 - Google Patents

Compuestos de piridina y su uso como antagonistas de p2 y12

Info

Publication number
CO6190618A2
CO6190618A2 CO09072491A CO09072491A CO6190618A2 CO 6190618 A2 CO6190618 A2 CO 6190618A2 CO 09072491 A CO09072491 A CO 09072491A CO 09072491 A CO09072491 A CO 09072491A CO 6190618 A2 CO6190618 A2 CO 6190618A2
Authority
CO
Colombia
Prior art keywords
alkyl
aryl
cycloalkyl
heterocyclyl
alkoxy
Prior art date
Application number
CO09072491A
Other languages
English (en)
Inventor
Thomas Antonsson
David Brown
Ruth Bylund
Fabrizio Giordanetto
Johan Johansson
Meter Bach
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39608896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6190618(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6190618A2 publication Critical patent/CO6190618A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Un compuesto de la fórmula I o una sal farmacéuticamente aceptable de este:dondeR1 representa R6OC(O), R7C(O), R16SC(O), R17S, R18C(S) o un grupo gll preferiblemente R1 representa R6OC(O) o R7C(O); R2 representa CN, halógeno (F, CI, Br, I), (C4-C8)alquil opcionalmente interrumpido por oxígeno y/u opcionalmente sustituido por OH, aril, cicloalquil, heterociclil; además R2 representa (C2-C3)alquil interrumpido por oxígeno; además R2 representa (C1-C3)alquil sustituido por uno o más de OH, aril, aril(C1-C3)alquiloxi, cicloalquil y heterociclil, con la condición de que cualquiera de dicho grupo OH debe estar al menos 2 átomos de carbono separado de cualquier oxígeno; además R2 representa (C1-C12)alcoxi insustituido, (C3-C6)cicloalquil, hidroxi(C1-C12)alquil, (C1-C12)alquilC(O), (C1-C12)alquiltioC(O), (C1-C12)alquilC(S), (C1-C12)alcoxiC(O), (C3-C6)cicloalcoxi, aril, arilC(O), aril(C1-C12)alquilC(O), heterociclil, heterociclilC(O), heterociclil(C1-C12)alquilC(O), (C1-C12)alquilsulfinil, (C1-C12)alquilsulfonil, (C1-C12)alquiltio insustituido, (C3-C6)cicloalquiItio, arilsuIfinil, ariIsulfonil, ariltio, aril(C1-C12)alquiltio, aril(C1-C12)aIquilsulfinil, aril(C1-C12)alquiIsulfonil, heterociclil(C1-C12)alquiltio, heterociclil(C1-C12)alquiIsuIfinil, heterociclil(C1-C12)alquilsulfonil, (C3-C6)cicloalquil(C1-C12)alquiltio, (C3-C6)cicloaIquil(C1-C12)alquilsulfinil, (C3-C6)cicloalquiI(C1-C1 2)alquilsulfonil; R4 representa H, CN, un átomo de halógeno (F, CI, Br, I), (C1-C12)alquil opcionalmente interrumpido por oxígeno y/u opcionalmente sustituido por OH, COOH, (C1-C6)alcoxicarbonil, o uno o más átomos de halógeno (F, CI, Br, I); además R4 representa hidroxi(C1-C12)alquil, (C1-C12) alcoxi donde el grupo alcoxi puede opcionalmente ser sustituido por uno o más átomos de halógeno (F, Cl, Br, I), OH y/o COOH y/o (C1-C6)alcoxicarbonil; además R4 representa aril(C1-C6)alquil, (C1-C12)alquilsulfinil, (C1-C12)alquilsulfonil, (C1-C12)alquiItio, (C3-C6)cicloalquil(C1- C12)alquilsulfinil, (C3-C6)cicloalquil(C1-C12)aIquilsulfonil, (C3-C6)cicloalquil(C1-C12)alcoxi, aril(C1-C6)alcoxi o un grupo de la fórmula NRa(4)Rb(4) en la cual Ra(4) y Rb(4) independientemente representan H, (C1-C12)alquil, ...
CO09072491A 2007-01-12 2009-07-13 Compuestos de piridina y su uso como antagonistas de p2 y12 CO6190618A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88465807P 2007-01-12 2007-01-12

Publications (1)

Publication Number Publication Date
CO6190618A2 true CO6190618A2 (es) 2010-08-19

Family

ID=39608896

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09072491A CO6190618A2 (es) 2007-01-12 2009-07-13 Compuestos de piridina y su uso como antagonistas de p2 y12

Country Status (18)

Country Link
US (2) US20080171732A1 (es)
EP (1) EP2111400A4 (es)
JP (1) JP2010515728A (es)
KR (1) KR20090096742A (es)
AR (1) AR064866A1 (es)
AU (1) AU2008203953A1 (es)
BR (1) BRPI0806529A2 (es)
CA (1) CA2674998A1 (es)
CL (1) CL2008000091A1 (es)
CO (1) CO6190618A2 (es)
EC (1) ECSP099481A (es)
IL (1) IL199439A0 (es)
MX (1) MX2009007429A (es)
PE (1) PE20081633A1 (es)
RU (1) RU2009123928A (es)
TW (1) TW200833335A (es)
UY (1) UY30866A1 (es)
WO (1) WO2008085117A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090312368A1 (en) * 2006-07-04 2009-12-17 Astrazeneca Ab Pyridine Analogues IV
WO2010005384A1 (en) * 2008-07-07 2010-01-14 Astrazeneca Ab Ketone pyridine analogues and their use in the treatment of cardiovascular disorders
JP2014051434A (ja) * 2010-12-28 2014-03-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体
WO2013033178A1 (en) 2011-08-30 2013-03-07 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
RU2602456C1 (ru) * 2015-10-20 2016-11-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ оценки активности ароматазы овариальных фолликулов
WO2017153235A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung
US10561145B2 (en) 2016-07-19 2020-02-18 Bayer Cropscience Aktiengesellschaft Fused bicyclic heterocycle derivatives as pesticides
TW202415651A (zh) 2022-07-29 2024-04-16 日商住友製藥股份有限公司 含氮飽和雜環衍生物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
WO2001057037A1 (en) * 2000-02-04 2001-08-09 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7018985B1 (en) * 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
JP3500429B2 (ja) * 2000-11-01 2004-02-23 現代自動車株式会社 ポリプロピレン樹脂組成物
FR2820057A1 (fr) * 2001-01-30 2002-08-02 Ct De Transfert De Technologie Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7388021B2 (en) * 2004-05-12 2008-06-17 Bristol Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
NZ551603A (en) * 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
EP1804819A4 (en) * 2004-10-04 2007-12-12 Univ Wayne State USE OF AROMATASE INHIBITORS FOR ENDOMETRIAL DILUTION IN THE PREPARATION OF SURGICAL PROCEDURES ON ENDOMETRIUM AND UTERUS
WO2006073361A1 (en) * 2005-01-06 2006-07-13 Astrazeneca Ab Novel pyridine compounds
JP2009501216A (ja) * 2005-07-13 2009-01-15 アストラゼネカ アクチボラグ 新規なピリジン類縁体
EP2044024A4 (en) * 2006-07-04 2011-06-29 Astrazeneca Ab NEW ANALOGUES OF PYRIDINE
CA2655629A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New pyridine analogues
US20090312368A1 (en) * 2006-07-04 2009-12-17 Astrazeneca Ab Pyridine Analogues IV

Also Published As

Publication number Publication date
US20100137277A1 (en) 2010-06-03
BRPI0806529A2 (pt) 2014-04-22
MX2009007429A (es) 2009-07-17
US20080171732A1 (en) 2008-07-17
EP2111400A4 (en) 2010-07-07
AR064866A1 (es) 2009-04-29
KR20090096742A (ko) 2009-09-14
JP2010515728A (ja) 2010-05-13
IL199439A0 (en) 2010-03-28
CA2674998A1 (en) 2008-07-17
AU2008203953A1 (en) 2008-07-17
RU2009123928A (ru) 2011-02-20
PE20081633A1 (es) 2009-01-18
WO2008085117A1 (en) 2008-07-17
TW200833335A (en) 2008-08-16
CL2008000091A1 (es) 2008-09-05
ECSP099481A (es) 2009-08-28
EP2111400A1 (en) 2009-10-28
UY30866A1 (es) 2008-09-02

Similar Documents

Publication Publication Date Title
CO6190618A2 (es) Compuestos de piridina y su uso como antagonistas de p2 y12
LTPA2020531I1 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
ECSP099395A (es) Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico
PE20120027A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes
CO6220952A2 (es) Nuevos derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida
PE20120002A1 (es) Derivados de benceno sustituido con glucopiranosilo como inhibidores de sglt2
TW200628430A (en) Phenanthrene derivatives
AR067185A1 (es) Agentes de naftalenisoxazolina para el control de plagas de invertebrados
ES2567311T3 (es) 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP
BRPI0809770B8 (pt) Composto e composição para controlar uma praga de invertebrados
MX2010008637A (es) Derivado de fenilpirrol novedoso.
AR053569A1 (es) Derivados de pirazol
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
AR054583A1 (es) Pantoprazol isotopicamente sustituido
CO6260009A2 (es) Derivados de ariloxiacetamida bi-o triciclicos saturados e insaturados y su uso como fungicidas
AR073158A1 (es) Metodo y composicion para modular el crecimiento de celulas madre
HK1164114A1 (en) Antidepressant containing heterocyclic compound having specific structure
TW200602456A (en) Anthracene compound and organic electroluminescent device including the anthracene compound
ATE547418T1 (de) Organische elektrolumineszenzvorrichtung
CO6300944A2 (es) Derivado de hidroxi-quinoxalin-carboxamida
AR064867A1 (es) Analogos de piridina viii 518
AR050250A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica
AR065724A1 (es) Macrolidos
AR053673A1 (es) Derivados de (1,2,4) - ditiazoli (di) , inductores de glutation - s- transferasa y nadph quinona oxido- reductasa , para profilaxis y tratamiento de condiciones adversas asociadas con citotoxicidad en general y apoptosis en particular

Legal Events

Date Code Title Description
FC Application refused